Archives of Pharmacal Research

, Volume 34, Issue 2, pp 331–337

Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration

Drug Actions


In an effort to develop an alternative formulation of paclitaxel (PTX) suitable for intravenous administration, PTX-loaded sterically stabilized solid lipid nanoparticles (SLNs) were prepared and their pharmacokinetics and biodistribution were investigated. The pegylated SLNs were comprised of trimyristin (TM) as a solid lipid core and egg phosphatidylcholine and pegylated phospholipid as stabilizers. The prepared pegylated TM-SLNs containing PTX exhibited monodispersed size distribution with 217.4 ± 32.8 nm of mean diameter and 99% of distribution was smaller than 556.2 ± 89.9 nm. After PTX in the pegylated TM-SLNs or commercial product, Taxol®, was intravenously administered into femoral vein of rats, concentrations of PTX in plasma and organs such as liver, spleen, kidney, heart and lung were analyzed by HPLC following liquid extraction. Plasma profile of PTX for pegylated TM-SLNs was similar to that for Taxol®, with no statistically significant difference at each time point, although mean plasma levels of PTX at each point tended to be slightly lower in pegylated TM-SLNs than in Taxol®. PTX in the pegylated TM-SLNs was taken up mainly into reticuloendothelial system showing 8-fold and 3-fold higher levels in liver and spleen, respectively, 8 h after administration compared to PTX in Taxol®. Meanwhile, PTX levels in kidney, heart and lung were not different between two formulations. There were no statistically significant differences in pharmacokinetic parameters. Taken together the results, the pegylated TM-SLNs provided similar circulation compared with commercial formulation, Taxol®.

Key words

Pegylated solid lipid nanoparticles Paclitaxel Pharmacokinetics Biodistribution 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Chen, D. B., Yang, T. Z., Lu, W. L., and Zhang, Q., In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull., 49, 1444–1447 (2001).PubMedCrossRefGoogle Scholar
  2. Devalapally, H., Chakilam, A., and Amiji, M. M., Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci, 96, 2547–2565 (2007).PubMedCrossRefGoogle Scholar
  3. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., and McNeil, S. E., Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm, 5, 487–495 (2008).PubMedCrossRefGoogle Scholar
  4. Fang, J., Nakamura, H., and Maeda, H., The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2010.04.009 (2010).Google Scholar
  5. Fundar, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., and Gasco, M. R., Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res, 42, 337–343 (2000).CrossRefGoogle Scholar
  6. Gao, Y., Gu, W., Chen, L., Xu, Z., and Li, Y., The role of daidzeinloaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials, 29, 129–136 (2008).CrossRefGoogle Scholar
  7. Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A., Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 37, 1590–1598 (2001).PubMedCrossRefGoogle Scholar
  8. Lee, M. K., Lim, S. J., and Kim, C. K., Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28, 2137–2146 (2007).PubMedCrossRefGoogle Scholar
  9. Nornoo, A. O. and Chow, D. S., Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int. J. Pharm, 349, 117–123 (2008).PubMedCrossRefGoogle Scholar
  10. Reddy, L. H., Vivek, K., Bakshi, N., and Murthy, R. S., Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm. Dev. Technol, 11, 167–177 (2006).PubMedCrossRefGoogle Scholar
  11. Sanjula, B., Shah, F. M., Javed, A., and Alka, A., Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target, 17, 249–256. (2009).PubMedCrossRefGoogle Scholar
  12. Singla, A. K., Garg, A., and Aggarwal, D., Paclitaxel and its formulations. Int. J. Pharm., 20, 179–192 (2002).CrossRefGoogle Scholar
  13. Souto, E. B. and Doktorovova, S., Solid lipid nanoparticle formulations: pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol, 464, 105–129 (2009).PubMedCrossRefGoogle Scholar
  14. Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., and Desai, N., Comparative preclinical and clinical pharmacokinetics of a cremophor-free nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin. Cancer Res, 11, 4136–4143 (2005).PubMedCrossRefGoogle Scholar
  15. Wall, E. M. and Wani, M. C., Camptothecin and Taxol; discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res, 55, 753–760 (1993).Google Scholar
  16. Wang, Y. and Wu, W., In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv., 13, 189–192 (2006).PubMedCrossRefGoogle Scholar
  17. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R. Jr., Van Echo, D. A., Von Hoff, D. D., and Leyland-Jones, B., Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263–1268 (1990).PubMedGoogle Scholar
  18. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., and Yang, C. Z., Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 59, 299–307 (1999).PubMedCrossRefGoogle Scholar
  19. Zhang, X., Pan, W., Gan, L., Zhu, C., Gan, Y., and Nie, S., Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull, 56, 1645–1650 (2008).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2011

Authors and Affiliations

  1. 1.College of PharmacyWoosuk UniversityJeonbukKorea

Personalised recommendations